

Press Release – For immediate release

BIOLIDICS ACCORDED THE PRESTIGIOUS “IPOS AWARD FOR IP CHAMPIONS” BY WIPO-IPOS

- **Testament to Biolidics’ technological advancements and commercialisation efforts in cancer diagnostics solutions with its novel, patented technology**
- **Strong boost to Biolidics’ plans to expand into new geographical markets in Southeast Asia for larger market outreach with its intellectual property portfolio and laboratory developed tests (“LDTs”) business model**

Singapore, 27 August 2019 – Biolidics Limited (“Biolidics” or the “Company”), a medical technology company with a focus on cancer diagnostic solutions, is pleased to announce today that it has been accorded the “IPOS Award for IP Champions” by the Intellectual Property Office of Singapore (IPOS) and the World Intellectual Property Organization (WIPO), the IP agency of the United Nations.

The WIPO-IPOS IP Awards 2019 Ceremony took place at IP Week@SG Opening Ceremony and the Minister for Trade and Industry, Mr. Chan Chun Sing, presented the “IPOS Award for IP Champions” to Mr. Ivan Lew, Executive Director and CEO of Biolidics. The WIPO-IPOS IP Awards 2019 is the pre-eminent accolade that celebrates companies that have achieved outstanding enterprise growth in innovation, transformation, and commercialisation through intellectual property and intangible assets.

The “IPOS Award for IP Champions” is awarded to the top three organisations in Singapore that have successfully achieved outstanding enterprise growth with a strong intellectual property and intangible assets strategy. Since its inception in 2013, a total of 21 organisations have been conferred the award.

Cancer remains one of the world’s biggest medical challenges and Biolidics’ technology, with its minimally invasive feature, is focused on many important unmet medical needs in this area that provide improved outcomes for individual patients.

The “IPOS Award for IP Champions” recognition was for Biolidics’ technological advancements and commercialisation efforts in cancer diagnostics solutions with its ClearCell® FX1 System, which allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Partnering with industry leaders and laboratories in China and Japan, Biolidics’ ClearCell® FX1 System as a platform technology for LDTs further enhances the commercial scalability of its technology and presents new opportunities to expand its offerings through services, partnerships and market expansion.

In addition to targeting the China and Japan cancer diagnostics market, Biolidics is looking to expand its LDT business model across Southeast Asia (“SEA”), which is experiencing rising rates of cancer with an expanding population of more than 640 million¹.

According to the 2014 World Cancer Report from the International Agency for Research on Cancer, which forms part of the World Health Organisation. It is estimated that about 60% of global cancer incidence occurs in developing countries, and rates across SEA are expected to surge in the coming years, reaching levels 40% higher by 2030 than those in 2012.

- END -

About Biolidics Limited

(Bloomberg Code: BLD:Singapore / Reuters Code: BIOL.SI / SGX Code: 8YY)

Incorporated in 2009, Biolidics is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated CE-IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

The ClearCell® FX1 System, installed across Asia, Europe and North America, allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post- cancer monitoring.

Biolidics’ quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA (formerly CFDA) Class I registration (for the MGI EasyCell System).

For additional information, please visit www.biolidics.com.

¹ <https://southeastasiaglobe.com/southeast-asias-race-to-combat-growing-cancer-crisis/>

Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.

Media & Investor Contacts:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

This press release has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.